Verbatim response from ChatGPT
Short answer
- Many people see the fastest losses in the first 3–6 months (often 5–10% of body weight), and continued but slower loss out to ~9–12 months.
- How much you lose depends on the drug/dose, your starting weight, how you use it (plus diet/exercise), and individual biology. Typical clinical-trial ranges: ~10–15% body weight at ~1 year with semaglutide 2.4 mg (Wegovy), and larger average losses — often 15–20% or more — with tirzepatide (Zepbound/Mounjaro) at higher doses. Lower-dose GLP-1s used for diabetes (Ozempic, Rybelsus) usually produce smaller losses (often 5–10%).
Is that weight loss sustainable?
- These drugs change appetite and energy balance, so they work well while you take them. Most evidence shows weight is maintained only while the medication continues; stopping commonly leads to partial or full regain unless you have strong, permanent lifestyle/behavior changes or another maintenance strategy. In other words, for many people GLP-1s become a long-term treatment for weight management rather than a short course that “fixes” the problem forever.
More detail and practical points
- Timeline: expect the quickest declines in months 1–6. Losses then slow and may plateau around 9–12 months. Individual response varies widely.
- Amount: approximate trial-based averages:
- Wegovy (semaglutide 2.4 mg) — roughly 10–15% average body‑weight loss at ~68 weeks.
- Zepbound (tirzepatide for obesity) / Mounjaro (tirzepatide for diabetes) — higher average losses seen in trials (often ~15–20% at higher doses over ~1 year).
- Saxenda (liraglutide) — approved for weight loss but generally smaller effects than semaglutide/tirzepatide.
- Ozempic (semaglutide for diabetes) and Rybelsus (oral semaglutide) — used off-label for weight loss in some cases and typically give more modest results than the approved high-dose Wegovy regimen.
- Side effects: common are nausea, vomiting, diarrhea, constipation, and decreased appetite. Rare but serious: pancreatitis, gallbladder problems, and a theoretical risk of certain thyroid tumors (contraindicated with personal/family medullary thyroid cancer or MEN2). Not for use in pregnancy.
- Practical: most regimens are started low and titrated up to reduce GI side effects. Insurance coverage varies and cost can be high without coverage.
- Best outcomes: combining medication with structured lifestyle support (diet, physical activity, behavioral counseling) and medical follow-up increases the chance of meaningful, sustained weight loss.
What to do next
- Talk with a clinician before starting a GLP‑1: discuss medical history, pregnancy plans, and medications. Ask about monitoring and a plan for long-term use or tapering.
- If you want specialist care, look for an ABOM-certified obesity medicine physician (Obesity Medicine Association has directories). For convenience, some telehealth services (for example, certain weight-management programs and telemedicine clinics) offer GLP‑1 consults — check credentials and local prescribing rules.
- If cost/coverage is a concern, ask your clinician about manufacturer savings programs and whether the product your insurer covers is the formulation/dose you need (Wegovy and Zepbound are approved for obesity; Ozempic/Mounjaro are diabetes formulations and coverage/labeling differs).
If you want, tell me:
- your starting weight/height (or percent over what you’d like to lose), any medical conditions or meds, and whether you want options that are covered by your insurance — I can give a more personalized expectation and next-step plan.